Targeted therapies: Expanding the use of PARP inhibitors
Nature Reviews Cancer 17, 397 (2017).
doi:10.1038/nrc.2017.50
Author: Sarah Seton-Rogers
Inhibition of poly(ADP-ribose) polymerase (PARP), which is part of the single-strand break DNA repair pathway, is synthetic lethal with BRCA1- or BRCA2-induced defects in the homologous recombination (HR) DNA repair pathway. Pharmacological PARP inhibitors (PARPis) have been successfully used in cancers with BRCA
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Sarah Seton-Rogers Tags: Research Highlight Source Type: research